Data on sprytne.com is aggregated from official U.S. Government sources including the SEC EDGAR database, USAspending.gov, USPTO, and U.S. Census Bureau. In accordance with 17 U.S.C. § 105, works of the U.S. Government are not subject to copyright protection and reside in the Public Domain. sprytne.com provides value-added visualization and algorithmic analysis of these public records.
Not financial advice. sprytne.com is an automated market intelligence platform. We are not a registered investment advisor, broker, or dealer. Financial metrics, risk scores, and federal award data are for informational purposes only. Past performance (including government contract history) is not indicative of future market results. Verify all data via official SEC.gov filings.
This platform adheres to CCPA/GDPR standards regarding professional and public business data. Information displayed pertains to commercial entities and public officers in their professional capacity. For data verification or removal requests regarding non-public information, please visit our Contact page. Operated under Brand House Data Systems framework.
© 2026 sprytne.com — Institutional Data Intelligence — Federal Transparency Initiative
Ticker ICLR · Nasdaq · US
25/100
ICON PLC is a U.S. business entity operating within the Commercial Physical & Biological Research sector (SIC 8731). Publicly traded on the Nasdaq under the ticker symbol ICLR, the company is actively registered in the United States. Our proprietary Semantic Risk Score of 34 indicates moderate transparency based on filing patterns, derived from the frequency and consistency of 10-K, 10-Q, and 8-K filing patterns.
Comparison based on Standard Industrial Classification (SIC) mapping from SEC EDGAR filings.
Federal Contracts
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
PHASE A THROUGH F - ICON. THIS CONTRACT IS FOR THE UNIVERSITY OF CALIFORNIA (UCB) AT BERKELEY SPACE SCIENCES LABORATORY, THE PRIME CONTRACTUAL INTERFACE FOR NASA FOR THE IONOSPHERIC CONNECTION EXPLORER (LCON) MISSION INVESTIGATION TEAM, THAT COVERS PHASE A OF THE MISSION. THE NASA AO IS NNHIIZDA0020. UNDER THE DIRECTION OF THE PRINCIPAL INVESTIGATOR (PI) DR. THOMAS IMMEL, UCB WILL BE THE PRINCIPAL CONTRACTOR TO NASA FOR ICON. UCB SHALL CONDUCT THE PHASE A CONCEPT STUDY IN ACCORDANCE WITH THE CONCEPT STUDY GUIDELINES. IN PERFORMANCE OF THIS STUDY, THE ICON TEAM SHALL: A. CONDUCT TRADE AND RISK REDUCTION STUDIES; B. UPDATE AND REFINE THE EXISTING MISSION COST ESTIMATES AND FINANCIAL PLAN; C. INTEGRATE AND DELIVER TO NASA ALL SUBCONTRACTOR AND UCB FINANCIAL REPORTS; D. DEVELOP PLAN FOR EARNED VALUE MANAGEMENT TO BE IN PLACE DURING PHASES C AND D; E. DEVELOP THE MISSION IMPLEMENTATION PLAN FOR PHASE B/CID, AND E; F. DEFME THE RISK MANAGEMENT PLAN AND DEVELOP MITIGATION STRATEGIES; G. OUTLINE THE FABRICATION, INTEGRATION, TEST, AND OPERATION OF THE SYSTEM; H. DEFINE THE EDUCATION, OUTREACH, TECHNOLOGY, AND SMALL BUSINESS DISADVANTAGED BUSINESS PLANS; I. DEVELOP A PRELIMINARY PERFORMANCE ASSURANCE IMPLEMENTATION PLAN (PAIP); J. DEVELOP A PRELIMINARY SYSTEMS ENGINEERING MANAGEMENT PLAN; K. DOCUMENT THE RESULTS OF THE STUDIES IN THE PHASE A CONCEPT STUDY REPORT; AND L. PRESENT THE ICON CONCEPT TO THE NASA ASSOCIATE ADMINISTRATOR.
ICON TASK ORDER AWARD
CLINICAL TRIAL SUPPORT
LABOR - BASE YEAR (3 MONTHS)
CLINICAL TRIAL PLANNING AND EXECUTION (CTPE)
FY22 SBIR PHASE III - DESIGN, DEVELOPMENT, FABRICATION TESTING, AND DELIVERY OF LUNAR CONSTRUCTION SYSTEM FOR DEMONSTRATION
200311!000486!9700!ZD10 !DISA, NATIONAL CAPITAL REGION !DCA10003C4016 !A!N! !N!P00003 !20030130!20040630!108649864!108649864!054781240!N!TELCORDIA TECHNOLOGIES, INC !ONE TELCORDIA DR !PISCATAWAY !NJ!08854!03000!013!51!ARLINGTON !ARLINGTON !VIRGINIA !+000000387900!N!N!000000000000!AD21!RDTE/SERVICES-BASIC RESEARCH !C9E!ALL OTHER SUPPLIES AND EQUIPME!1000!NOT DISCERNABLE OR CLASSIFIED !518210!E! !3! ! !D! ! !99990909!B! ! !A! !D!U!U!1!001!N!1A!Z!N!Z! ! !N!C!N! ! ! !A!A!A!A!000!A!B!N! ! ! !Y! !HC1001!0001! !
Contract details pending disclosure
PHASE I CLINICAL TRIAL UNIT FOR THERAPEUTICS AGAINST INFECTIOUS DISEASES
Source: USAspending.gov (Official Federal Award Data). Reflects prime contracts only. Last sync: 2026-03-30.
Compared to 17 peers in Commercial Physical & Biological Research (SIC 8731)
Side-by-side financial showdown — revenue, margins, and growth.
America's #1 crypto exchange. Buy Bitcoin, Ethereum & 200+ coins.
Get Started Free →Affiliate link · sprytne.com may earn a commission
Methodology & compliance note
Data is aggregated from SEC EDGAR and Secretary of State public records. Any analytics such as "market share" are statistical estimates (proxy models) and are not official audits, valuations, or investment advice. Sprytne.com is an independent data aggregator and is not affiliated with any government agency.Learn more →